Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Global Blood Ther (NQ: GBT ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Global Blood Ther < Previous 1 2 3 4 Next > Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report August 05, 2022 Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline. Via Benzinga Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday August 05, 2022 U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session August 04, 2022 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session August 04, 2022 Via Benzinga Recap: Global Blood Therapeutics Q1 Earnings May 04, 2022 Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Via Benzinga Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday August 05, 2022 Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... Via Benzinga Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session August 04, 2022 Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. Via Benzinga Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session August 04, 2022 Via Benzinga Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket August 04, 2022 Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday. Via Benzinga Why Global Blood Therapeutics Stock Is Surging After Hours August 03, 2022 Global Blood Therapeutics Inc (NASDAQ: GBT) shares are soaring in Wednesday's after-hours session following a report suggesting the company is attracting takeover interest. Via Benzinga 7 Small-Cap Growth Stocks With 1,000% Upside Potential July 31, 2022 Here're 7 small-cap growth stocks with 1,000% upside potential. ACLS, AXSM, GBT, GPRO, HCAT, SKLZ, and VERU can make great investments. Via InvestorPlace Recap Of Tuesday's Biotech Catalysts - End of The Day Summary July 26, 2022 Via Benzinga Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate July 26, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying July 06, 2022 Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. Via Investor's Business Daily Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 July 05, 2022 Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. Via Investor's Business Daily Looking Into Global Blood Therapeutics's Return On Capital Employed June 28, 2022 According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of... Via Benzinga How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing June 10, 2022 The company is using a different approach to tackle the blood disease. Via Investor's Business Daily 7 No-Brainer Biotech Stocks to Add to Your Buy List June 09, 2022 With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. Via InvestorPlace Global Blood Therapeutics Earnings Perspective: Return On Capital Employed May 20, 2022 According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42... Via Benzinga Looking Into Global Blood Therapeutics's Return On Capital Employed April 26, 2022 Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58... Via Benzinga What 4 Analyst Ratings Have To Say About Global Blood Therapeutics February 28, 2022 Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Recap: Global Blood Therapeutics Q4 Earnings February 23, 2022 Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement... Via Benzinga The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development February 23, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... Via Benzinga The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa February 16, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... Via Benzinga The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow February 20, 2022 Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... Via Benzinga Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics February 02, 2022 Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. Via Benzinga The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks January 13, 2022 Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? Via Investor's Business Daily FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years December 20, 2021 The FDA has granted accelerated approval to Global Blood Therapeutics Inc's (NASDAQ: GBT) supplemental application seeking approval for Oxbryta (voxelotor... Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session December 17, 2021 Gainers GBS (NASDAQ:GBS Via Benzinga Global Blood Raises $300M Via Convertible Debt Offering December 15, 2021 Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering. The offering size was increased from... Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.